| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 8, 2009
Eisai Corporation of North America today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental new drug application (sNDA) for an...
-
Jul 2, 2009
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime Shimizu) are...
-
Jul 1, 2009
Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, announced a research collaboration agreement with Synageva BioPharma Corporation to express and develop therapeutic...
-
Jun 9, 2009Antibody Targets Endosialin, a Protein Widely Expressed on Tumors and Tumor Blood Vessel Cells
Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, announced that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application to study...
-
Jun 1, 2009Eisai Inc. and the Alzheimer's Association Support Award to Recognize Critical Role of Pharmacists in Alzheimer's Care
Eisai Inc., in coordination with the Alzheimer's Association, calls on individuals with Alzheimer's disease and their caregivers across America to nominate local pharmacists for the 2009 C.A.R.E....
